StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
INDCT.OL$1.85-8.42%
Fair $1.85+0.0%

INDCT.OL

Induct AS

Healthcare / Health Information ServicesOslo

$1.85

-0.17 (-8.42%)

Fairly Valued+0.0%Fair Value $1.85Fund rank 31/100 · Data gapFallback financials|
SA 21/D
F-Score: 6/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 23%

FCF escenarios

weak_data · normalized FCF $-7.3M · quality 67.0/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 31/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

21/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years ROE is -17.4%, below the 5% threshold
Thesis & Journal · INDCT.OLLocal privado en este navegador · Induct AS
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$58M

P/E

N/A

•

EV/EBITDA

8.1x

↓

ROE

-17.4%

↓

Gross Margin

92.9%

↑

Debt/Equity

0.09

↓
52-Week Range$2
$2$5

TradingView lightweight chart

INDCT.OL price, volumen y niveles de valoración

Último $1.850Periodo -95.2%
Fair value: $1.850

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-8.7%

FCF CAGR

—

FCF margin

-22.3%

FCF / Net income

0.46x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $14.8M · net income $-7.1M · FCF $-3.3M

2022-FY → 2025-FY

Gross margin

92.9%-4.4% pts

Operating margin

-36.1%-3.4% pts

Net margin

-48.1%+4.8% pts

FCF margin

-22.3%+110.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$14.8M$14.8M$18.0M$21.0M$19.4M
Net Income$-7.1M$-7.1M$-20.6M$-5.0M$-10.3M
EBITDA$7.3M$7.3M$-4.0M$8.1M$7.2M
EPS-0.23-0.23-0.86-0.26-0.58
Gross Margin92.9%92.9%82.1%95.0%97.3%
Operating Margin-36.1%-36.1%-72.1%-14.4%-32.7%
Net Margin-48.1%-48.1%-114.7%-23.7%-52.8%
Balance Sheet
Debt/Equity0.090.090.160.220.16
Current Ratio0.940.94———
Cash Flow
Free Cash Flow$-3.3M$-3.3M$-12.0M$-7.3M$-25.7M
Returns
ROE-17.4%-17.4%-77.8%-21.9%-34.8%
Valuation
EV/EBITDA8.108.10—12.5615.71
P/B1.421.421.994.303.76
Growth & Yield
Revenue Growth-17.7%-17.7%-14.6%8.3%—
EPS Growth73.6%73.6%-230.4%55.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -48.0%

Total return

-48.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.86 → -0.23

Residual

-48.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-48.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.